Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproate for schizophrenia.

A Basan1, S Leucht

  • 1Psychiatrische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, München, Germany.

The Cochrane Database of Systematic Reviews
|February 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same author

Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

Physical review letters·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Valproate augmentation for schizophrenia showed a faster onset of action but no significant long-term benefits. Further research is needed to determine its efficacy in specific patient groups.

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Neuroscience
  • Evidence-Based Medicine

Background:

  • Many individuals with schizophrenia exhibit inadequate responses to standard antipsychotic treatments.
  • Valproate is frequently utilized as an adjunctive therapy for treatment-resistant schizophrenia.
  • The efficacy of valproate in schizophrenia requires comprehensive evaluation.

Purpose of the Study:

  • To systematically review the effects of valproate in treating schizophrenia and schizophrenia-like psychoses.
  • To assess valproate's efficacy as a monotherapy and as an adjunct to antipsychotic medications.

Main Methods:

  • Conducted a systematic search of the Cochrane Schizophrenia Group's register up to July 2002.
  • Included randomized controlled trials comparing valproate with antipsychotics or placebo.

Related Experiment Videos

  • Independently assessed study quality and extracted data, analyzing dichotomous data using relative risks and continuous data using weighted mean differences.

    • Main Results:

    • Five small, short-term studies (379 participants) evaluated valproate as an adjunct to antipsychotics.
    • Valproate augmentation did not significantly improve global or mental state compared to placebo.
    • While one study indicated a quicker onset of action, participants receiving valproate experienced more sedation.

    Conclusions:

    • Current evidence does not support or refute valproate as a sole agent for schizophrenia.
    • Limited evidence suggests a transient benefit in symptom improvement with valproate augmentation.
    • Further large, well-designed trials are necessary, focusing on specific subgroups like violent or treatment-resistant patients.